# Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure

> **NCT01082094** · PHASE1 · COMPLETED · sponsor: **Juventas Therapeutics, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **BIOLOGICAL:** ACRX-100

## Key facts

- **NCT ID:** NCT01082094
- **Lead sponsor:** Juventas Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082094, "Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01082094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*